PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Researchers find PCSK9 inhibitors could treat abdominal aortic aneurysms

The condition is responsible for 2,200 annual deaths in the UK.

UK researchers have discovered that drugs that treat high cholesterol could slow the development of abdominal aortic aneurysms (AAA).

The study, led by the University of Leicester’s Professor Matthew Bown and partly funded by the British Heart Foundation (BHF), found that PCSK9 inhibitors could be repurposed as a treatment for people with an AAA.

AAA, responsible for 2,200 deaths in the UK each year, is a swelling in the aorta that carries blood away from the heart and around the body.

After performing a genome-wide association study and analysing the DNA to search for risk-increasing genes in over 39,000 people with an AAA, the researchers identified 141 genetic variants in the development of aneurysms, one of which encoded the PCSK9 protein.

Currently used as a treatment for individuals with high cholesterol, PCSK9 inhibitors stop the breakdown of cholesterol receptors to boost the body’s ability to remove bad cholesterol from the blood.

By simulating the effect of PCSK9 inhibitors in mice with an AAA, the researchers found that the growth of aneurysms slowed.

Additionally, aneurysms grew particularly slowly in mice with an AAA that lacked the PCSK9 protein in comparison to those with the functioning protein.

Professor James Leiper, associate medical director at BHF, said: “Repurposing drugs which have already been shown to be safe and effective, such as PCSK9 inhibitors, can dramatically shorten the time it takes for findings to go from discovery to patient trials.

“While testing in large groups of patients will be needed before these drugs can be recommended, these promising results offer hope to thousands of AAA patients that their long wait for a treatment may soon be over.”

Findings from the study could help guide the search for more treatments for AAA, which currently has no cure.

The research was also funded by the Health Research Council of New Zealand, the Veterans Administration Office of Research and Development, Tobacco-Related Disease Research Programs and the National Institutes of Health.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026